Dehydroepiandrosterone (DHEA)

Overview

Dehydroepiandrosterone (DHEA) is an endogenous steroid hormone precursor produced primarily by the adrenal cortex, specifically the zona reticularis, as described in the document. It plays a central role in the biosynthesis of androgens and estrogens and circulates predominantly in its sulfated form (DHEA-S). Dehydroepiandrosterone levels peak in early adulthood, typically around the mid-twenties, and then gradually decline with advancing age.

The document outlines DHEA’s broad physiological importance, including its role in pubertal development, metabolic regulation, immune modulation, and potential neuroprotective effects. Because of these functions, Dehydroepiandrosteron assessment is used to evaluate adrenal gland function, investigate androgen excess or deficiency, and support diagnosis and monitoring of various endocrine disorders. Dehydroepiandrosterone is also noted for its clinical relevance in aging, stress responses, and adrenal pathology.

Symptoms

Abnormal dehydroepiandrosterone levels do not cause symptoms directly; instead, symptoms arise from the underlying hormonal imbalance or adrenal dysfunction, as outlined in the document.

Low DHEA levels may be associated with symptoms such as:

1. Fatigue and reduced energy
2. Low libido
3. Memory impairment
4. Depression or mood changes
5. Osteoporosis

Elevated DHEA levels may be associated with:

1. Signs of androgen excess
2. Precocious puberty
3. Virilisation in females
4. Menstrual irregularities
5. Unexplained alopecia

The document highlights that symptom patterns vary by age, sex, and clinical context, and that Dehydroepiandrosteron abnormalities may be identified during evaluation of adrenal tumours, congenital adrenal hyperplasia, polycystic ovary syndrome, or unexplained hormonal symptoms.

Causes

Altered dehydroepiandrosterone levels result from changes in adrenal steroid production or regulation, as detailed in the document. Dehydroepiandrosteron secretion is regulated by adrenocorticotropic hormone (ACTH), with feedback mechanisms influenced by downstream androgen and estrogen conversion.

Causes of low DHEA levels include:

1. Adrenal insufficiency
2. Natural age-related decline
3. Hypopituitarism or pituitary disorders
4. Chronic illness or severe stress
5. Use of glucocorticoids or hormonal therapies
6. Hypothyroidism
7. Malnutrition or significant weight loss
8. Organ failure affecting the liver or kidneys

Causes of elevated DHEA levels include:

1. Congenital adrenal hyperplasia
2. Adrenal tumours or hyperplasia
3. Androgen-secreting tumours
4. Polycystic ovary syndrome
5. Premature adrenarche or puberty
6. Exogenous DHEA supplementation

The document emphasizes that physiological variation, stress, circadian rhythm, and medications can also influence dehydroepiandrosterone concentrations.

Risk Factors

Risk factors for abnormal dehydroepiandrosterone levels are closely related to adrenal function, endocrine regulation, age, and systemic health, as described in the document.

Key risk factors include:

1. Advancing age, due to natural hormonal decline
2. Presence of adrenal or pituitary disorders
3. Chronic stress or severe illness
4. Autoimmune diseases
5. Long-term steroid or hormone therapy
6. Conditions causing androgen excess or deficiency
7. Metabolic or endocrine disorders affecting hormone balance

The document notes that Dehydroepiandrosterone values must be interpreted with consideration of age- and sex-specific reference ranges, as normal levels differ significantly across life stages. Risk assessment is most effective when dehydroepiandrosterone is evaluated alongside other hormonal and clinical findings.

Prevention

Abnormal Dehydroepiandrosterone production cannot always be prevented, particularly when related to aging or genetic conditions. Prevention, therefore, focuses on early detection, accurate interpretation, and avoidance of misleading results, as emphasized in the document.

Preventive and best-practice measures include:

1. Testing Dehydroepiandrosteron at appropriate times, considering diurnal variation
2. Discontinuing Dehydroepiandrosterone supplements before testing
3. Accounting for age, sex, stress, and medication effects
4. Avoiding haemolysed samples and ensuring proper serum handling

From a clinical perspective, prevention also involves:

1. Identifying adrenal or pituitary disorders early
2. Using Dehydroepiandrosterone measurement alongside other hormonal tests
3. Avoiding reliance on dehydroepiandrosterone alone to localize androgen excess
4. Correlating laboratory values with clinical presentation

The document stresses that DHEA results must be clinically correlated and interpreted cautiously to prevent overdiagnosis or mismanagement. Prevention, in this context, is aimed at preventing diagnostic errors, inappropriate supplementation, and misinterpretation of physiological variations, thereby supporting accurate endocrine assessment and patient care.